Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
Status:
Active, not recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating
patients with melanoma that has spread to other places in the body or cannot be removed by
surgery. Monoclonal antibodies, such as pembrolizumab and ipilimumab, may interfere with the
ability of tumor cells to grow and spread. Aspirin may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving pembrolizumab, ipilimumab, and
aspirin may work better in treating patients with melanoma.